1,7-phenanthroline has been researched along with Multiple Myeloma in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Anderson, KC; Carrasco, RD; Chauhan, D; Das, DS; Li, S; Munshi, N; Qi, J; Ray, A; Samur, MK; Song, Y; Tai, YT | 1 |
Badillo Patzmay, GV; Kwiecień, A; Lupidi, G; Nabissi, M; Pettinari, C; Pettinari, R; Santoni, G; Smoleński, P; Wołoszyn, A | 1 |
2 other study(ies) available for 1,7-phenanthroline and Multiple Myeloma
Article | Year |
---|---|
Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Mice; Multiple Myeloma; Phenanthrolines; Prognosis; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Trans-Activators; Ubiquitination; Xenograft Model Antitumor Assays | 2017 |
Ru(ii)-(PTA) and -mPTA complexes with N
Topics: 2,2'-Dipyridyl; Adamantane; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coordination Complexes; Crystallography, X-Ray; Humans; Multiple Myeloma; Nitrogen; Organophosphorus Compounds; Phenanthrolines; Ruthenium | 2017 |